How Long Will FDA Take on Your GRAS Notice?

Dr. Bryan Quoc Le · Mendocino Food Consulting · November 2026

A GRAS notice now takes about nine to ten months from the day FDA receives it to the day FDA responds, and a growing share of that wait happens before the official review clock even starts. FDA's proposal to make notification mandatory could stretch it by years unless review capacity grows. Here is what 1,360 notices show, and how to plan an ingredient launch around it.

The problem: FDA's 180-day clock starts later than you think

If you're bringing a new ingredient to market, you've probably heard that FDA responds to a GRAS notice within 180 days, with a possible 90-day extension.

That's true, as far as it goes. But those 180 days start when FDA files your notice, not when FDA receives it. And the gap between the two has grown a lot.

For a small company, that gap is real money. Launch dates, fundraising rounds, co-packer slots and retailer resets all get planned around the day you'll have FDA's letter in hand.

Now FDA has proposed making GRAS notification mandatory. Its own analysis expects about 98.5 more full notices a year, plus thousands of one-time submissions for ingredients already on the market. So the question is: How long will the wait be once everyone has to get in line?

What I did

I went through every notice in FDA's public GRAS Notice Inventory: 1,360 notices, from 1998 to 2026. I sorted each one into one of 15 ingredient classes, from enzymes and sweeteners to precision-fermentation proteins and algal biomass.

FDA's inventory stopped listing filing dates around 2017, and it never lists receipt dates. But FDA's response letters usually say both: "We received your notice on … and filed it on …". So I pulled those dates out of 642 FDA letters.

Then I measured how long each step takes, and built a simple queue model using the numbers in FDA's own economic analysis of the proposed rule.

The full methods, data and limitations are in the technical report. To estimate the timeline for your own ingredient, use the free GRAS Timeline Estimator.

What I found

1. The wait before review begins has grown about four-fold. In 2016–2018, FDA filed a typical notice within about a month of receiving it. Since 2020, the median wait has been three to seven months.

Counted from receipt, the typical notice takes about 289 days to get a response. Only about 1% of notices received in 2025 closed within 180 days of receipt. In 2017, 29% did.

This isn't FDA breaking its own rules. FDA can meet a 180-day standard measured from filing while notices wait months to be filed. It's a measurement gap, and it's one the public inventory no longer shows.

2. The program is already running at full capacity. From 2021 to 2025, FDA closed about 69 notices a year and took in about as many. When a system has no slack, small bumps in demand turn into longer waits instead of clearing. For notices filed in 2020–2022, 40–54% ran past 270 days, the full 180 days plus the extension.

3. Your ingredient type matters. Novel ingredients take longer and are more often withdrawn. Enzymes, microbial strains and sweeteners move fastest.

Median days from filing to a "no questions" letter, and the share of closed notices where the notifier asked FDA to stop evaluating. All closed notices, 1998–2026.

"Ceased to evaluate" usually means FDA raised questions the notifier couldn't answer quickly, and the notifier pulled the notice. It's the outcome you most want to avoid, and for some classes it happens to about a third of notices.

4. The proposed rule would need about 2.4× today's review capacity. FDA expects about 98.5 more full notices a year. That raises inflow from about 69 to about 168 a year. FDA's analysis estimates the staff hours per notice, but not the calendar time, the staffing or the backlog.

So I modeled it. If FDA reviews full notices ahead of the one-time streamlined submissions, and capacity stays where it is, the extra wait for a new full notice is about 2.8 years in the first year of the rule, growing to 8.5 years by the fifth. At 1.5× today's capacity, it's still 1.5 to 4 years. At 2.5×, it settles at about five months.

These are scenarios, not forecasts. FDA could add staff, triage notices or phase in the streamlined submissions. The point is the size of the gap the rule has to close, and that its economic analysis doesn't yet address it.

Five ways to plan an ingredient launch around the wait

Whether you're filing your own notice or relying on a supplier's, these five steps keep the regulatory timeline from setting your launch date for you.

• Count from receipt, not filing. Plan on three to five months before FDA files your notice, then six to eight months of review. The estimator does the math for your ingredient class.
• Know your class's track record. If you're working with biomass, novel proteins or botanicals, budget for the 90-day extension and for FDA questions.
• Get the dossier right the first time. A pre-submission meeting with FDA and a complete, well-organized safety narrative are the best protection against a "cease to evaluate" ending.
• Keep commitments flexible until filing. Don't lock in a co-packer slot, a retailer reset or a fundraising milestone to a date that depends on FDA's letter.
• Watch the final rule. If notification becomes mandatory, timing will matter: Submitting before the rule takes effect may avoid the worst of the queue. Ask regulatory counsel what the final rule allows while a notice is pending.

About the author

I'm Dr. Bryan Quoc Le, a food scientist and the founder of Mendocino Food Consulting. I've spent more than ten years in food product development, and I'm the author of 150 Food Science Questions Answered. I've worked with companies from early-stage startups to Blue Diamond Growers and The Good Food Institute.

Planning a launch around a new ingredient? Send me your ingredient, its intended use and your target launch date at bryan@mendocinofoodconsulting.com, and I'll help you map a realistic timeline. That's the core of my Second Opinion Call.